This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I Study in Patients With Solid Tumours

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: July 3, 2007
Last updated: September 21, 2010
Last verified: September 2010
This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.

Condition Intervention Phase
Neoplasms Drug: AZD0530 Drug: Carboplatin Drug: Paclitaxel Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate the safety and tolerability of AZD0530 in combination with carboplatin and/or paclitaxel regimens with solid tumours by assessment of AEs, physical examination, BP, pulse, ECG, laboratory findings, PFTs and thoracic CT scans. [ Time Frame: Assessed at each visit ]

Secondary Outcome Measures:
  • To determine the Maximum Tolerated Dose of AZD0530 when administered in combination with carboplatin and/or paclitaxel by assessment of safety and tolerability data generated for each treatment arm. [ Time Frame: Assessed at each visit ]
  • To make a preliminary evaluation of clinical response by assessment of RECIST evaluation, time to progression and serum tumour markers. [ Time Frame: Assessment at end of study ]
  • To investigate the PK of AZD0530. paclitaxel and carboplatin when co-administered to patients with solid tumours, by assessment of appropriate PK parameters. [ Time Frame: Predetermined timepoints after dose administration ]

Enrollment: 148
Study Start Date: March 2007
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AZD0530 + Paclitaxel
Drug: AZD0530
oral tablet
Drug: Paclitaxel
intravenous infusion
Experimental: 2
AZD0530 + Carboplatin
Drug: AZD0530
oral tablet
Drug: Carboplatin
intravenous infusion
Experimental: 3
AZD0530 + Carboplatin + Paclitaxel
Drug: AZD0530
oral tablet
Drug: Carboplatin
intravenous infusion
Drug: Paclitaxel
intravenous infusion


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Life expectancy > 12 weeks
  • Women defined as post-menopausal
  • Male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel

Exclusion Criteria:

  • Inadequate bone marrow reserve
  • Inadequate live function, renal function or low haemoglobin
  • Unresolved toxicity from anti-cancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00496028

Research Site
Paris, France
Research Site
Pierre Benite Cedex, France
Research Site
Amsterdam, Netherlands
Research Site
Groningen, Netherlands
Research Site
Oslo, Norway
United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Sutton, United Kingdom
Sponsors and Collaborators
Principal Investigator: Steinar Aamdal, MD Radium Hospital, Norway
Study Director: Mary Stuart, MD AstraZeneca
  More Information

Responsible Party: Mary Stuart, MD - Medical Science Director EPT1, AstraZeneca Pharmaceuticals Identifier: NCT00496028     History of Changes
Other Study ID Numbers: D8180C00023
AZD0530 study 23
Study First Received: July 3, 2007
Last Updated: September 21, 2010

Keywords provided by AstraZeneca:
Solid tumors
locally advanced or Metastatic Cancer suitable for treatment with carboplatin and/or paclitaxel

Additional relevant MeSH terms:
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors processed this record on August 18, 2017